Citius Oncology, Inc. (CTOR) stock
CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.52−0.03 (-5.87%)
Close on Nov 12, 2026Market cap $48.56MP/E –Yield –
Citius Oncology EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Citius Oncology's EPS for the twelve months ending Jun 30, 2026 was -$0.47. For fiscal 2025 it was -$0.34, down 4161.2% from the year before.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$0.34 | -4161.2% |
| FY2022 | Dec 31, 2022 | $0.01 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$0.08 | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$0.27 | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$0.06 | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$0.06 | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$0.08 | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$0.11 | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$0.09 | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $0.00 | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?